NANOBIOTIX financials
Also U.S.-listed. NANOBIOTIX is also a foreign private issuer filing with the U.S. SEC. View its EDGAR financials: NBTX — Nanobiotix S.A.
NANOBIOTIX
Country: FR Reporting currency: EUR Latest annual report: 2025-12-31
LEI:
969500667RSYIH8YL895 Financial statements
(EUR, as reported — unscaled; 88 line items across 2 annual periods)
| Line item | 2025 | 2024 |
|---|---|---|
| Income statement | ||
| Other income | €3.0M | €4.4M |
| Operating expenses | €43.4M | €61.2M |
| Operating profit (EBIT) | -€10.8M | -€68.4M |
| Net finance income / (cost) | -€13.1M | €361.0K |
| Finance costs | €15.2M | €7.5M |
| Income tax expense | €3.0K | €101.0K |
| Profit for the year | -€24.0M | -€68.1M |
| Total comprehensive income | -€24.0M | -€68.2M |
| Per share | ||
| Basic EPS | €-0.50 | €-1.44 |
| Diluted EPS | €-0.50 | €-1.44 |
| Free cash flow / share | €-0.71 | €-0.43 |
| Cash flow statement | ||
| Net cash from operating activities | -€33.4M | -€19.6M |
| Income taxes paid | €198.0K | €62.0K |
| Net cash from investing activities | -€578.0K | -€955.0K |
| Purchase of PP&E (capex) | €538.0K | €846.0K |
| Purchase of intangibles | €8.0K | €2.0K |
| Net cash from financing activities | €37.4M | -€5.1M |
| Proceeds from borrowings | €42.9M | €0 |
| Repayments of borrowings | €3.5M | €3.1M |
| Lease liability payments | €1.2M | €1.1M |
| Balance sheet | ||
| Total assets | €67.8M | €67.4M |
| Non-current assets | €5.0M | €6.0M |
| Current assets | €62.8M | €61.5M |
| Trade & other receivables | €2.1M | €3.0M |
| Cash & equivalents | €52.8M | €49.7M |
| Total equity | -€84.5M | -€65.7M |
| Non-current liabilities | €94.7M | €74.2M |
| Current liabilities | €57.5M | €58.9M |
| Derived metrics | ||
| Free cash flow | -€34.0M | -€20.4M |
| Operating margin | -36.5% | 589.1% |
| Net margin | -80.8% | 586.9% |
| Return on equity | 28.4% | 103.7% |
| Cash conversion ratio | 1.39× | 0.29× |
| Capex coverage | -62.12× | -23.11× |
| Other reported items | ||
| Accumulated Other Comprehensive Income | €693.0K | €712.0K |
| Adjustments For Decrease Increase In Trade Account Receivable | €840.0K | -€2.1M |
| Adjustments For Depreciation and Amortisation Expense | €1.5M | €1.6M |
| Adjustments For Gain Loss On Disposals Property Plant and Equipment | -€153.0K | €3.0K |
| Adjustments For Income Tax Expense | €3.0K | €101.0K |
| Adjustments For Increase Decrease In Deferred Income Including Contract Liabilities | -€16.0K | €12.2M |
| Adjustments For Increase Decrease In Other Current Liabilities | €175.0K | -€224.0K |
| Adjustments For Increase Decrease In Trade and Other Payables | -€5.4M | €2.0M |
| Adjustments For Provisions | -€225.0K | -€263.0K |
| Adjustments For Sharebased Payments | €3.5M | €4.3M |
| Cash Flows From Used In Operations Before Changes In Working Capital | -€29.8M | -€33.8M |
| Current Deferred Income Other Than Current Contract Liabilities | €45.0K | €61.0K |
| Current Provisions | €118.0K | €438.0K |
| Dividends Proposed Or Declared Before Financial Statements Authorised For Issue But Not Recognised As Distribution To Owners | €0 | — |
| Dividends Proposed Or Declared Before Financial Statements Authorised For Issue But Not Recognised As Distribution To Owners Per Share | €0.00 | — |
| Dividends Recognised As Distributions To Owners Per Share | €0.00 | — |
| Effect of Exchange Rate Changes On Cash and Cash Equivalents | -€402.0K | €94.0K |
| Equity and Liabilities | €67.8M | €67.4M |
| Finance Income | €2.1M | €7.8M |
| Income Tax Relating To Components of Other Comprehensive Income That Will Not Be Reclassified To Profit Or Loss | €0 | €0 |
| Income Tax Relating To Exchange Differences On Translation of Other Comprehensive Income | €0 | €0 |
| Income Tax Relating To Hedges of Investments In Equity Instruments of Other Comprehensive Income | €2.0K | €0 |
| Increase Decrease In Cash and Cash Equivalents | €3.0M | -€25.5M |
| Increase Decrease In Working Capital | €3.4M | -€14.3M |
| Increase Decrease Through Appropriation of Retained Earnings | €0 | €0 |
| Increase Decrease Through Sharebased Payment Transactions | €3.5M | €4.3M |
| Intangible Assets Other Than Goodwill | €10.0K | €7.0K |
| Interest Paid Classified As Financing Activities | €1.5M | €980.0K |
| Issue of Equity | €1.7M | €0 |
| Issued Capital | €1.5M | €1.4M |
| Liabilities | €152.2M | €133.1M |
| Noncurrent Financial Assets | €434.0K | €406.0K |
| Noncurrent Provisions For Employee Benefits | €507.0K | €432.0K |
| Other Adjustments For Noncash Items | -€160.0K | €0 |
| Other Comprehensive Income | -€18.0K | -€27.0K |
| Other Comprehensive Income Before Tax Exchange Differences On Translation | -€36.0K | €6.0K |
| Other Comprehensive Income Before Tax Gains Losses On Remeasurements of Defined Benefit Plans | €19.0K | -€33.0K |
| Other Comprehensive Income Net of Tax Exchange Differences On Translation | -€36.0K | €6.0K |
| Other Comprehensive Income Net of Tax Gains Losses On Remeasurements of Defined Benefit Plans | €18.0K | -€33.0K |
| Other Comprehensive Income That Will Be Reclassified To Profit Or Loss Net of Tax | -€36.0K | €6.0K |
| Other Comprehensive Income That Will Not Be Reclassified To Profit Or Loss Net of Tax | €18.0K | -€33.0K |
| Other Operating Income Expense | €64.0K | -€134.0K |
| Payments For Share Issue Costs | €777.0K | €0 |
| Proceeds From Issue of Ordinary Shares | €1.5M | €0 |
| Property Plant and Equipment Including Rightofuse Assets | €4.6M | €5.5M |
| Purchase of Other Longterm Assets Classified As Investing Activities | €32.0K | €107.0K |
| Research and Development Expense | €23.1M | €40.5M |
| Retained Earnings Excluding Profit Loss For Reporting Period | -€376.8M | -€312.2M |
| Retained Earnings Profit Loss For Reporting Period | -€24.0M | -€68.1M |
| Revenue From Contracts With Customers | €29.6M | -€11.6M |
| Selling General and Administrative Expense | €20.4M | €20.5M |
| Share Premium | €314.4M | €312.7M |
| Trade and Other Current Payables To Trade Suppliers | €9.1M | €20.0M |
| Treasury Shares | €228.0K | €228.0K |
Methodology
Every line item above is a fact tagged in NANOBIOTIX's annual report
filed in the European Single Electronic Format (ESEF) under the IFRS
taxonomy (ifrs-full) — the income statement, balance sheet
and cash-flow statement as the filer reported them. Values are shown
as-is, in the reporting currency (EUR), without
rescaling; the row labels map to the underlying concept name (e.g.
Revenue → ifrs-full:Revenue, Operating profit →
ifrs-full:ProfitLossFromOperatingActivities, Diluted EPS →
ifrs-full:DilutedEarningsLossPerShare), and any concept
without a curated label is shown under “Other reported items” with its
de-camel-cased tag name. Only consolidated, default-member facts are
shown (segment / dimensional breakdowns are excluded).
“Derived metrics” (free cash flow, margins, ROE, …) are computed from those facts by the same model the U.S. financials pages use — not tagged by the filer.
Source: machine-readable OIM xBRL-JSON aggregated by filings.xbrl.org (XBRL International). Entity identity is resolved by LEI via the public-domain GLEIF register. This is reference data, not investment advice.